Addressing the needs of patients with hemophilia and other bleeding disorders is an important NIH priority. Currently supported NIH research relevant to the many complications of these disorders includes studies to:
The NIH fully intends to continue and expand work in these areas. The NIH institutes are, for example, planning new research efforts for the coming year that will address such issues as factors affecting the progression of HCV infection in hemophilia patients and other frequently transfused populations, development of safer and more effective vectors for gene transfer, and induction of immune tolerance to factor VIII. The intermediate goal is to prevent, reduce, or eliminate the many complications that afflict patients with hemophilia and other bleeding disorders so that they can lead normal, healthy lives. The ultimate goal is to cure the disorders themselves.